June 8, 2008 - At the European Academy of Allergology and Clinical Immunology (EAACI 2008) in Barcelona, ALK-Abelló presented successful results from a new clinical trial, GT-12, designed to measure the impact of GRAZAX® on allergic rhinitis and allergic asthma. GT-12 compared the effects of GRAZAX® with symptomatic medication versus symptomatic medication alone on the ability to reduce symptoms of allergic rhinitis and seasonal asthma. A significant reduction of asthma symptoms was demonstrated. GRAZAX® reduced a combined asthma symptom score by 64%. The asthma symptoms included were: coughing, wheezing, chest tightening/shortness of breath (dyspnoea) and exercise induced symptoms. Participants in the study also experienced a 67% reduction in the number of days with asthma symptoms (median)... ALK-Abelló's Press Release -
